Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)
The investigators will examine efficacy and toxicity of gefitinib in Korean patients with EGFR wild tumors diagnosed with direct sequence test.
Nonsmall Cell Lung Cancer
DRUG: salvage iressa
To determine disease control rate at 8 weeks will be 35% or higher in the the study group, 6 months after the enrollment of the last patients
The number of patients who live longer than 6 months after enrollment, 6 months after the enrollment of the last patients
The investigators will examine efficacy and toxicity of gefitinib in Korean patients with EGFR wild tumors diagnosed with direct sequence test.